81
64
Growth Score
-5 pts
Heat Score
13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
494679
Retmarker artificial intelligence technology makes the Diabetic Retinopathy annual screening objective, scalable and affordable.
Gonçalo Quadros: Co-founder
Frederico Teles: Engineering Manager
Meteda
About the Company
Retmarker, a patented and certified medical device, is a biomarker for Diabetic Retinopathy progression.
Diabetic Retinopathy is the eye-sight complication of Diabetes (382 Million today and 592 Millions estimated in 2035) and the leading cause of blindness in the working population. To avoid blindness, all Diabetics should be screened at least
once a year in order to provide early and timely treatment.
Retmarker has been used with success in Diabetic Retinopathy Screening Programs since 2011. The aim of Retmarker is not to replace doctors and specialists, rather to provide efficient solutions that empower them to provide the best healthcare to those threatened by Diabetic Retinopathy.
